Constellation Pharmaceuticals Inc (NASDAQ: CNST) received a Buy rating and a $21 price target from Oppenheimer analyst Leah R. Cann today. The company’s shares closed on Friday at $9.85.
Cann observed:
“We are initiating coverage of Outperform rating and a 12-18-month $21 target price. A development-stage biotechnology company, Constellation is using epigenetics to address prostate cancer, as well as other solid tumors, and using protein-protein interaction to treat myelofibrosis.”
According to TipRanks.com, Cann is a 5-star analyst with an average return of 20.8% and a 54.3% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Constellation Pharmaceuticals Inc with a $21 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $12.21 and a one-year low of $9.00. Currently, Constellation Pharmaceuticals Inc has an average volume of 262.1K.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CNST in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Constellation Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery, develeopment, and provision of biopharmaceutical products. It researches and develops small molecule therapeutics for the treatment of cancer, inflammatory and immunologic disorders. Its products include CPI-1205, CPI-0209, and CPI-0610.
